RAPT on track to initiate trial this year. SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-base ...
Collectively, these findings provide the rationale and foundation for the innovative adaptive design of AdvanCell’s ongoing Phase 1b/2 TheraPb trial of ADVC001 (NCT05720130), the Company’s ...
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung ...
In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) ...
KDIGO 2025 guideline recommends a lower threshold for biopsy to enable earlier diagnosis and recommends aiming for stricter proteinuria control, with a goal of <0.5 g/day, ideally <0.3 g/day, which ...
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated commercial-stage biotechnology company with innovative marketed products and a pipeline of development candidates, today ...
Following the 2 most recent cases of anaphylaxis, Larimar consulted its experts and decided to modify its starting dose regimen; Larimar provided the FDA a full update on the clinical development ...
The Company is awaiting the receipt of official meeting minutes from the FDA in order to determine next steps. At this time, a path forward regarding a potential submission strategy for regulatory ...
A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset ...
On January 29, 2025, Inventiva announced the publication in Journal of Hepatology of the results of the investigator-initiated proof-of-concept clinical trial led by Dr. Kenneth Cusi, demonstrating ...
MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback